THE PROSTATE CANCER FOUNDATION AND BAYER ANNOUNCE FIRST EVER BAYER-PCF DAROLUTAMIDE CHALLENGE AWARDS streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Latest Vitrakvi® (larotrectinib) Subgroup Analyses at ASCO 2023 Showcase Long-Term Efficacy and Safety Profile in Adult and Pediatric Patients with NTRK Gene Fusion Cancer, Across Solid Tumors streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Findings presented at the American Society of Clinical Oncology (ASCO) 2023 meeting show the long-term efficacy and safety profile of larotrectinib (Vitrakvi; Bayer) in solid tumors with NTRK gene fusion.